Regeneron Pharmaceuticals, Inc.(REGN)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
REGN | 76.40 B | 18.95x | 16.70% | 27.87% | $39.17 | 14.04% | 8.54x | 0.50% | $859.34 | $541.00 |
VRTX | 128.16 B | 29.67x | 12.50% | 35.00% | $17.04 | 23.54% | 9.77x | 0.00% | $560.25 | $400.74 |
ALNY | 30.03 B | 41.63x | 66.90% | 16.13% | $5.39 | 96.56% | 2.21x | 0.00% | $495.55 | $197.81 |
CRSP | 5.06 B | - | 1041.40% | 0.00% | -$4.72 | -26.10% | 0.45x | 0.00% | $78.48 | $44.12 |
RXRX | 2.29 B | - | -60.10% | 0.00% | -$0.99 | -56.58% | 7.28x | 0.00% | $7.18 | $2.77 |
NTLA | 1.64 B | - | -46.20% | 0.00% | -$3.36 | -55.44% | 0.10x | 0.00% | $28.25 | $7.95 |
Peer Valuation & Performance Analysis
Peer group analysis for Regeneron Pharmaceuticals, Inc. (REGN) compared to its primary competitors (including VRTX, ALNY, CRSP) reveals distinct metrics. REGN trades at a valuation premium compared to its competitors, with a P/E ratio of 18.9x versus the peer average of 10.5x (representing a 81% premium). This indicates that the market expects superior growth or commands a quality premium for REGN. In terms of growth, REGN's revenue growth of 16.7% lags behind the peer average of 202.9%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 27.9% compared to the peer average of 10.2%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• REGN ranks #1 in P/E ratio, #3 in revenue growth, and #2 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $738.05 | $753.68 | $734.18 | $742.12 | 626,400 | +0.46% |
| 2026-10-06 | $734.61 | $740.51 | $727.16 | $738.72 | 615,100 | +1.69% |
| 2026-10-05 | $734.37 | $736.42 | $722.02 | $726.47 | 694,700 | -1.19% |
| 2026-10-02 | $740.50 | $742.50 | $729.20 | $735.20 | 613,900 | +0.05% |
| 2026-10-01 | $766.53 | $777.43 | $726.02 | $734.81 | 1,042,800 | -3.09% |
| 2026-09-30 | $749.84 | $763.72 | $742.94 | $758.27 | 872,400 | +1.03% |
| 2026-09-29 | $745.85 | $752.47 | $741.83 | $750.51 | 804,300 | -0.23% |
| 2026-09-28 | $778.09 | $780.95 | $750.00 | $752.25 | 1,149,800 | -4.54% |
| 2026-09-25 | $803.87 | $803.87 | $784.13 | $788.04 | 592,100 | -1.00% |
| 2026-09-24 | $801.59 | $807.21 | $789.39 | $796.02 | 602,600 | -0.72% |
| 2026-09-23 | $805.23 | $813.53 | $790.02 | $801.82 | 721,100 | -0.26% |
| 2026-09-22 | $802.48 | $811.66 | $791.31 | $803.90 | 600,200 | +0.72% |
| 2026-09-21 | $786.03 | $801.44 | $779.96 | $798.17 | 704,400 | +1.70% |
| 2026-09-18 | $787.34 | $794.73 | $779.65 | $784.85 | 2,472,600 | -0.58% |
| 2026-09-17 | $781.18 | $789.99 | $774.78 | $789.45 | 702,800 | +1.92% |
Explore More Analysis for REGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.